Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H10O5S |
| Molecular Weight | 254.259 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(CC(=O)C2=CC=CC=C2C1=O)S(O)(=O)=O
InChI
InChIKey=WIXFIQKTHUVFDI-UHFFFAOYSA-N
InChI=1S/C11H10O5S/c1-11(17(14,15)16)6-9(12)7-4-2-3-5-8(7)10(11)13/h2-5H,6H2,1H3,(H,14,15,16)
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3927923 | https://www.ncbi.nlm.nih.gov/pubmed/18935165 | https://www.ncbi.nlm.nih.gov/pubmed/26212258
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/3927923 | https://www.ncbi.nlm.nih.gov/pubmed/18935165 | https://www.ncbi.nlm.nih.gov/pubmed/26212258
Menadione bisulfite is a water-soluble analog of Vitamin K3. Pharmacologic studies on menadione bisulfate indicad that its toxicity is relatively low. In man, doses approximately ten times as great as those generally recommended for therapeutic use, given daily for a period of one week. Redox cycling compounds, such as menadione, have the potential to effectively mitigate the toxicity of organophosphorus pesticides including parathion. Menadione bisulfite behaved as a competitive inhibitor of chicken muscle aldose reductase.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL5035 |
|||
Target ID: CHEMBL2169730 |
|||
Target ID: Aldose reductase (Gallus gallus) |
0.025 mM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 mg 10 times / day multiple, oral Highest studied dose Dose: 10 mg, 10 times / day Route: oral Route: multiple Dose: 10 mg, 10 times / day Co-administed with:: Vitamin C, p.o(500 mg; 10 times/day) Sources: Page: p.64 |
unhealthy, 56 – 85 n = 3 Health Status: unhealthy Condition: Prostate cancer Age Group: 56 – 85 Sex: M Population Size: 3 Sources: Page: p.64 |
Sample Use Guides
5 mg. Therapy, averaging thirty days, was continued until the withdrawal of metlication produced no recurrence of symptoms.
Route of Administration:
Oral
Addition of menadione bisulfite (3 mM) alone to the perfusate increased oxygen uptake by 20-30 uM/g/hr. In the presence of ethanol, maximal increases in oxygen uptake due to menadione bisulfite were much larger (about 90 uM/g/hr), and lactate dehydrogenase release occurred earlier and reached higher maximal values (330 units/g/hr).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
I2BE1ZEN8I
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
63930
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
8536
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
300000029211
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY | |||
|
130-36-9
Created by
admin on Fri Dec 15 15:55:57 GMT 2023 , Edited by admin on Fri Dec 15 15:55:57 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
